Summary.-Thirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pretreatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytotoxicity (using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders (statistically significant for direct cytotoxic capacity) but not in responders when compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall" -antigen skin testing showed no statistically significant difference between the patient groups.
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The data indicate that "non-T-cell activity" may be associated with response to chemo -immunotherapy.
IMMUNOLOGICAL
investigation of malignant melanoma has been the subject of considerable research. However, much of this work has concentrated on attempts to demonstrate "specific" immunity to melanoma antigens. Humoral and cellular cytotoxic assays have been employed in the search; some authors describing tumour "specificity" Fossati et al., 1971) whilst others have been unable to demonstrate such reactions Takasugi, Mickey and Terasaki, 1973) .
One explanation for the failure to demonstrate a specific tumour-associated response is that a high level of non-specific cytotoxicity present in both healthy controls and melanoma patients could mask any "specific" cytotoxicity present The study of non-specific lymphocyte cytotoxicity per se in melanoma has been infrequently documented and no reports are available which describe the relationship between pre-treatment immune reactivity and response to chemo-immunotherapy.
The present investigation was undertaken to determine whether patients with metastatic melanoma (prior to chemoimmunotherapy) were different from healthy controls in terms of non-specific cytotoxicity, and T and B lymphocyte sub-populations and whether lymphocyte function assays were different in patients who subsequently responded to chemoimmunotherapy, from those who were unresponsive. In addition, some patients were studied sequentially, to determine whether an association exists between Various assays were employed, including delayed hypersensitivity skin reaction (to recall antigens) peripheral-blood lymphocyte counts, formation of EAC sheep rosettes (a B-lymphocyte marker, (Bianco, Patrick and Nussenzweig, 1970) ) E sheep rosettes, a T-lymphocyte marker, (Lay et al., 1971; Jondal, Holm and Wigzell, 1972 ) and a 51Cr-release assay of lymphocyte effector function. In the 5ICr-release assay the following parameters were studied: direct spontaneous cellular cytotoxicity, antibody-dependent cellular cvtotoxicity (MacLennan and Loewi, 1968; Perlmann and Holm, 1968) , and PHA-stimulated cellular cytotoxicity, (Holm, Perlmann and Werner, 1964; Holm, and Perlmann 1967) against Chang target cells.
Antibody-dependent cellular cytotoxicitv is a function of "non-T cells" (Harding et al., 1971) , but the effector cell ("K" cell) is different from B cells, which are precursors of antibody-forming cells (MacLennan, 1972) . The PHA-stimulated cytotoxicity appears to be mediated by T cells (Perlmann and Holm, 1969; O'Toole et al., 1974) . The identity to the human effector cell, responsible for spontaneous non-specific cytotoxicity is unclear. It has been reported to bear Fe receptors (Jondal and Pross, 1.975; Hersev et al., 1975) and is found in the non-T-cell population  (2 mg). The courses wiere repeated (up to a total of 6) every 28 days. BCG was given between courses of chemotherapy, 10 days from the start of the preceding course. Dried BCG vaccine, percutaneous (Glaxo) was -econstituted in 0-3 ml sterile wAater and administered by a multiplepuncture gun. Two applications of vaccine (40 needle punctures, set at a 2 mm depth) were given to each limb. BCG administration was contrinued at monthly intervals followN-ing completion of 6 courses of chemotherapy.
Response to therapy w-as taken as a 50% or greater reduction in diameter of a measurable lesion, lasting at least 2 months and writhout disease progression elsewhere.
In the sequential study, the patients' blood samples were obtained at the start of each course of chemotherapy and also, where possible, on the day of BCG vaccination.
Tests of lymphocyte rosetting ability were not undertaken in a sequential manner in this particular study, due to logistic difficulties. All the patients in this study completed at least 3 courses of chemotherapy, and sequential immune studies are available over at least a 4-month period ( Figs. 1 and 2 ).
The normal controls w\ere 14 individuals employed in the hospital service and 7 relatives of patients (Table 1I ). The median age of controls wA-as 51 Vears (range 32-68) and of the patients 49 years (range 22-75).
Tuberculin PPD (1:1000) 0.1 ml (Evans Mledical Ltd, Speke, Liverpool, U.K.) SKSD (10 u Streptokinase, 2-5 u Streptodornase) 0-1 ml (Lederle Labs, Pearl River, N.Y., After standing at 37°C in a 5% C02 incubator for 20 h, the tubes were centrifuged and 0 5 ml supernatant transferred to empty tubes and counted on a gamma counter. The ct/min was punched on to a paper tape which was processed by a digital computer. 
RESULTS
The two patient groups, responders and non-responders, and the normal control group were compared for differences in lymphocyte count, DCC, ADCC, PCC, E rosette %0, EAC rosette %0, "null" cell %0 and the absolute E, EAC and null-cell counts. Cytotoxic capacity (Go MCR x lymphocyte count) was also calculated for DCC, ADCC and PCC for individual subjects and the median values compared.
Non-parametric statistical techniques have been used because of non-normality of data. As there were 3 groups, the KruskalWallis "one-factor analysis of variance for ranks" was used initially and, if statistically significaiit, each pair of groups was then contrasted using the Mann- Whitney U test at a reduced level of statistical significance (100).
The distribution of metastases was similar in the responder and non-responder patient groups (Table III) . There was no other obvious clinical difference between these two groups before systemic therapy commenced.
The lymphocyte count, cytotoxic capacity for DCC and ADCC, E rosette and "null" cell counts were found to be significantly different between the 3 groups using the Kruskal-Wallis test (Table IV) . The additional analysis demonstrated that the difference was statistically significant between the non-responder and control groups, with the following P values: lymphocyte count 0'001, DCC Analysis of the other test values revealed that the differences between the groups were not statistically significant, although examination of median values showed a consistent pattern between the 3 groups (Table IV) .
The median values of the responder group: lymphocyte count 1536; DCC 18-1; ADCC 55-1; PCC 5741 and their cytotoxic capacity (179, 566, 570 respectively), were all higher than in the non-responder group, 1440, 11 0, 37 7, 44-8 and 66, 251, 313 The values of E rosette % for the non-responders (68.6), responders (66.3) and normals (67.5) showed very little difference. The EAC rosette %, however, was higher in non-responders (29.1) than in responders (23.9) and controls (21.9). The skin reactivity to "recall" antigens was similar in both patient groups. The responder group showed 10/33 positive (33-3%) in the non-responding group.
The sequential study of lymphocyte cytotoxicity included 5 patients who were non-responders (Fig. 1) , 3 who were responders and one untreated patient with "stable" disease (Fig. 2) . The untreated patient. D.M. showed much less variation in sequential tests than the patients undergoing chemo-immunotherapy.
Comparison of sequential cytotoxicity values for the individual patients showed no significant changes. The patients' results were also pooled for similar occasions, but again no significant difference was found between the cytotoxicity values, using a Friedman 2-way nonparametrical analysis.
DISCUSSION
This study demonstrates differences in lymphoid-cell function between melanoma patients and healthy controls. It also suggests a difference in pre-treatment lymphoid-cell function between patients who subsequently respond and those who fail to respond to systemic therapy. The 2 patient groups ("responder", "nonresponder") at the time of immunological investigation were clinically similar, particularly with regard to the distribution of metastases (Table III) . It is, therefore, unlikely that clinical response or the immunological profile were dictated by a particular pattern of metastatic desease.
However, this does not necessarily imply that the pre-treatment tumour burden was the same in both patient groups. It might be expected that if the "responders" had a smaller tumour mass than the "nonresponders", they would be more likely to respond to therapy. Patient tumour mass is as yet impossible to quantitate precisely, but in the present investigation, there was no obvious difference between the two groups.
The lymphocyte count was significantly less in the non-responder patient group than in the healthy control group. The median lymphocyte count for the responder group was also lower than that of the control group, but higher than that of the non-responder group; the differences between patient groups were not however significant. This relationship between response and lymphocyte count has not previously been clearly defined, although lymphopenia has, in some series, been related to poor survival (Riesco, 1970; Papatestas and Kark, 1974 (Anthony et al., 1975; Peter et al., 1975; Whitehead et al., 1976) . The presence of null cells in the present study was associated with lack of response. The increase in null-cell number is partly a reflection of the reduction in E-and EAC-rosette numbers, and it is not possible to determine whether the lack of response was associated with reduced E-rosette levels alone or whether the change in null cells was also important. A (Catalona, Sample and Chretien, 1973) but is at variance with reports of normal skin reactivity (Ziegler et al., 1969) and of the clinical significance attached to such tests (Morton et al., . However, the use of "skin test reactivity" shouild be encouraged, despite the present and other reports that lack statistically significant differences, as it is the only in vivo method routinely available for immunological evaluation of patients.
Immune reactivity in vitro has been related to tumour stage in some studies; "tumour-specific "cellular immunity being greater in localised than in generalised disease (Cochran et al., 1973 ) and a reduction in immunity being associated with advancing disease (de AVries, Rumke and Bernheim 1972; Heppner et al., 1973) . However, other authors, using PHAinduced lymphocyte blastogenesis have found either no difference between patients and controls (Ziegler et al., 1969; Catalona et al., 1973) or a depression in melanoma patients unrelated to the clinical situation (Lui et al., 1975; Gatti, G4arrioch and Good, 1970) . Lymphocyte microcytotoxicity assays have also failed to relate to response rates (Vanwijck, Bouillenne and Malek-Mansour, 1975; Catalona et al., 1973; Berkelhammer et al., 1975) . Little attention has been directed at "K"-cell activity as measured by ADCC, but lower reactivity in cancer patients than in normal controls has been noted (Ting and Terasaki, 1974; Peter et al., 1975) . However, the relationship with response to therapy was not commented upon.
In the present study, a consistent pattern of cytotoxicity was seen in the 3 groups. The medians for the responder patients showed no immunodepression relative to controls. However, "non-T-cell" (DCC, ADCC) cytotoxicitv was depressed in the non-responders. But, this depression was only statistically significant if "non-T-cell" function was expressed in terms of the lymphocyte count. The calculation is analagous to that used in generating the rosetting-cell counts. The implication is also similarthat the "total" cytotoxicity of a functionally defined subpopulation might be a more biologically meaningful number to use in statistical analysis.
The sequential study of cytotoxicity in 8 patients failed to demonstrate any consistent pattern with repeated courses of chemotherapy and BCG vaccination. However, these patients, both responders and non-responders, did exhibit more fluctuation in cytotoxicity than the untreated patient with "stable" disease (Figs. 1, 2) or normal controls assaved on several occasions (Thatcher et al., 1977) suggesting perturbation of cytotoxicity by the chemo-immunotherapy and/or by alteration in tumour load. A similar lack of clinical correlation with a microcytoxicity assay has been noted in melanoma patients receiving immunotherapy alone (Berkelhammer et al., 1975) .
This investigation suggests that a high level of "non-T-cell" cytotoxicity might be important for a successful therapeutic outcome in metastatic melanoma. The median values of the DCC and ADCC assays (albeit only significantly different for "DCC capacity") were greater in responders, than in non-responders, and might be a reflection of the higher concentrations of non-E-rosetting cells circulating in these patients. Although T-cell numbers and PCC were higher in responders than in non-responders, the level of PCC was near normal in the latter group and, furthermore, these differences in PCC were not statistically significant. A relationship between "non-T-cell" cytotoxicity and clinical response might therefore be postulated.
